Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 496 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 496 shares of the company’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $119.09, for a total value of $59,068.64. Following the transaction, the chief financial officer now directly owns 74,314 shares of the company’s stock, valued at approximately $8,850,054.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The stock was sold at an average price of $120.76, for a total value of $73,422.08.
• On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90.
• On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $102.77, for a total transaction of $127,229.26.
• On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The shares were sold at an average price of $105.29, for a total transaction of $72,650.10.

Natera Stock Performance

Shares of NASDAQ:NTRA traded down $1.30 during midday trading on Wednesday, hitting $118.65. The stock had a trading volume of 632,741 shares, compared to its average volume of 1,331,355. The company has a market capitalization of $14.57 billion, a PE ratio of -38.03 and a beta of 1.53. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $133.54. The stock has a 50 day moving average price of $123.43 and a two-hundred day moving average price of $111.03. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.97) EPS. As a group, equities analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. TD Cowen upped their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Canaccord Genuity Group raised their price target on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Stephens reiterated an “overweight” rating and issued a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. Finally, Morgan Stanley lifted their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $124.44.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. Vanguard Group Inc. increased its holdings in shares of Natera by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after purchasing an additional 72,848 shares in the last quarter. Farallon Capital Management LLC grew its position in Natera by 13.6% during the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after buying an additional 532,874 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Natera by 6.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock valued at $259,634,000 after buying an additional 148,917 shares in the last quarter. Duquesne Family Office LLC lifted its position in shares of Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after acquiring an additional 45,500 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after acquiring an additional 246,246 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.